Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sponsor Initiated Requests to Delay Pediatric Postmarketing Studies.

Pharmaceutical medicine·2026
Same author

Lifespan trajectories of serum sphingolipids in a clinically healthy Swiss population, towards precision medicine in cardiometabolic health assessment.

Communications medicine·2026
Same author

Effect of Incentivizing Pediatric Studies on the Development of Pediatric-Friendly Formulations.

The AAPS journal·2026
Same author

Access to Pediatric-Friendly Formulations at the Time of Pediatric Labeling and After Marketing.

Pediatrics·2025
Same author

Paediatric developmental safety and the ICH E11A extrapolation of safety.

British journal of clinical pharmacology·2025
Same author

Pediatric Developmental Safety Assessment: Are We Ready for the Next Thalidomide?

Clinical pharmacology and therapeutics·2025
Same journal

Hemangiomas: Beyond the Skin.

Pediatrics in review·2026
Same journal

More Than Innocent: A Continuous Murmur in an Infant.

Pediatrics in review·2026
Same journal

Genetic Testing.

Pediatrics in review·2026
Same journal

Visual Diagnosis: Term Infant With a Hemorrhagic Dermatologic Lesion.

Pediatrics in review·2026
Same journal

Long-Term Complications of Sickle Cell Disease.

Pediatrics in review·2026
Same journal

Pediatric Multisystemic Illness With Cardiac Involvement: A Diagnostic Challenge.

Pediatrics in review·2026
See all related articles

Related Experiment Video

Updated: May 10, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Pediatric pharmacokinetics.

Jonathan Wagner1, Susan M Abdel-Rahman

  • 1Section of Cardiology and Division of Clinical Pharmacology and Medical Toxicology, Department of Pediatrics, Children's Mercy Hospital, University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA.

Pediatrics in Review
|June 5, 2013
PubMed
Summary
This summary is machine-generated.

Understanding pharmacokinetics, including volume of distribution, clearance, and half-life, is vital for drug decisions. Drug disposition involves complex processes, and age-related physiological changes impact drug efficacy and toxicity.

More Related Videos

Microsurgical Skills of Establishing Permanent Jugular Vein Cannulation in Rats for Serial Blood Sampling of Orally Administered Drug
08:28

Microsurgical Skills of Establishing Permanent Jugular Vein Cannulation in Rats for Serial Blood Sampling of Orally Administered Drug

Published on: December 14, 2021

Related Experiment Videos

Last Updated: May 10, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Microsurgical Skills of Establishing Permanent Jugular Vein Cannulation in Rats for Serial Blood Sampling of Orally Administered Drug
08:28

Microsurgical Skills of Establishing Permanent Jugular Vein Cannulation in Rats for Serial Blood Sampling of Orally Administered Drug

Published on: December 14, 2021

Area of Science:

  • Pharmacology
  • Drug Metabolism and Disposition

Background:

  • Drug disposition encompasses absorption, distribution, metabolism, and excretion (ADME).
  • Aberrations in ADME can significantly alter drug efficacy and toxicity.
  • Physiological changes, particularly during development, influence drug disposition.

Purpose of the Study:

  • To elucidate the critical pharmacokinetic parameters influencing clinical decisions.
  • To highlight the complexity of drug disposition processes.
  • To emphasize the importance of considering age-dependent physiological changes in drug therapy.

Main Methods:

  • This article is a review and synthesis of pharmacokinetic principles.
  • It focuses on the theoretical underpinnings of drug disposition.
  • No specific experimental methods are detailed.

Main Results:

  • Key pharmacokinetic parameters include volume of distribution, elimination clearance, and elimination half-life.
  • Drug efficacy and toxicity are directly linked to the processes of ADME.
  • Age-related anatomical and physiological variations necessitate tailored dosing strategies.

Conclusions:

  • Understanding fundamental pharmacokinetic parameters is essential for safe and effective pharmacotherapy.
  • Drug disposition is a dynamic process influenced by numerous factors.
  • Individualizing drug therapy based on pharmacokinetic profiles and patient-specific changes is crucial for optimizing treatment outcomes.